AI-Driven Advances in ATTR-CM Care

Guest: Frederick Ruberg, MD Artificial intelligence has rapidly advanced disease recognition in transthyretin amyloid cardiomyopathy (ATTR-CM), and its role in guiding treatment selection, predicting progression, and refining prognosis is now being explored. Discover what's next in ATTR-CM care with Dr. Frederick Ruberg, Chief of Cardiovascular Medicine at Boston Medical Center and Thomas J. Ryan Professor of Cardiovascular Medicine at Boston University Chobanian & Avedisian School of Medicine.